Combination treatment for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two targeted drugs together for people with advanced breast cancer that is hormone receptor positive and has low levels of a protein called HER2. The goal is to see if this combination helps shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer is hormone receptor positive and has low or very low levels of HER2.
- Your cancer is advanced (can't be removed by surgery or has spread to other parts of the body).
- You have tried at least one hormone therapy and your cancer progressed while on it.
- You have taken a CDK4/6 inhibitor (like palbociclib, ribociclib, or abemaciclib).
- You have not had chemotherapy for advanced breast cancer (chemo before surgery is okay).
- You are generally in good health (able to carry out daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapies (patritumab deruxtecan plus pembrolizumab) along with other anticancer drugs for people with a high-risk type of early-stage breast cancer that is either triple-negative or has very low hormone receptors and is HER2-negative. The goal is to see if this approach can help prevent the cancer from coming back.
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
This trial tests a new drug, patritumab deruxtecan, combined with other anti-cancer drugs for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. It aims to see if these combinations can shrink tumors or slow cancer growth.
This study tests an investigational drug called patritumab deruxtecan for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The drug targets a protein called HER3, which is common on these cancer cells, and may slow or shrink the cancer when previous treatments have stopped working.
This Phase 2 trial tests patritumab deruxtecan (U3-1402) in people with HER2-negative, hormone-receptor positive (HR+) breast cancer that cannot be removed by surgery or has spread. It’s for cancers that have progressed despite endocrine therapy plus a CDK4/6 inhibitor, aiming to shrink tumors and control the disease.
This trial tests a combination of two drugs that target HER2-positive breast cancer: trastuzumab deruxtecan (currently the standard) plus a newer drug called pyrotinib. The goal is to see if combining these drugs helps people whose cancer has continued to grow despite taking trastuzumab deruxtecan alone.
Hear when a new Hormone Receptor Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.